Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2021

View Archived Issues

FDA clears IND for phase I/II study of LION-101 gene therapy as treatment of LGMD2I/R9

First-in-human trial of the PET ligand [68Ga]DOTA-Siglec-9 targeting vascular adhesion protein 1

Preclinical results presented for a gene therapy to treat CDHR1-related retinopathy

Promising liver-specific AAV gene therapy for glycogen storage disease type 1A

Amgen initiates phase I study of AMG-994 alone and with AMG-404 in advanced solid tumors

Prosit Sole initiates phase I study of interferon lambda chimera injection PSP-001

Telix reports data from phase I/IIa study of TLX-66 in AL amyloidosis

New G12C mutant KRAS inhibitors discovered at Beijing Jacobio Pharmaceuticals

New opioid receptor agonists identified at Fudan University

Tango Therapeutics presents new PRMT5 inhibitors

Hangzhou Bangshun Pharmaceutical decribes new RET inhibitors

Bioardis patents CD73 inhibitors

Amino acid composition AXA-1665 beneficial in Child-Pugh A and B patients

Studies reveal efficacy of OTL-101 gene therapy in treating ADA-SCID

NFlection presents positive phase IIa data for NFX-179 gel

Jasper collaborates with NIAID to evaluate JSP-191 in chronic granulomatous disease

SPX-1009 leads to suppression of melanoma cells

Janssen initiates first-in-human trial of JNJ-75276617 in acute leukemia

Enrollment ongoing in phase I study of IBI-322 in hematologic malignancies

Novel RIPK2 inhibitor for the treatment of IBD

GGT7 as new prognostic biomarker in gastric cancer

Start of phase II/III EMPATHY trial of ensovibep for treatment of COVID-19

Study casts new light on chronic HCV infection

Aptevo reports phase I data on APVO-436 in AML and MDS

First-in-human study of ZB-716 for ER-positive, HER2-negative advanced breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...